Impact of glycopeptide resistance in Staphylococcus aureus on the dalbavancin in Vivo pharmacodynamic target

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 12, 2015, Pages 7833-7836

  Lepak, A ^a   Marchillo, K ^a   VanHecker, J ^a   Andes, D ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALBAVANCIN; GLYCOPEPTIDE; ANTIINFECTIVE AGENT; DAPTOMYCIN; TEICOPLANIN; VANCOMYCIN;

ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; IN VIVO STUDY; LEG DISEASE; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TANDEM MASS SPECTROMETRY; THIGH INFECTION; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; ANALOGS AND DERIVATIVES; ANIMAL; AREA UNDER THE CURVE; BLOOD; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; INTRAPERITONEAL DRUG ADMINISTRATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY; STAPHYLOCOCCAL INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; INJECTIONS, INTRAPERITONEAL; MICE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEICOPLANIN; VANCOMYCIN;

EID: 84954540679     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01717-15     Document Type: Article

References (32)

1. Chambers HF. 2005. Community-associated MRSA: resistance and virulence converge. N Engl J Med 352:1485-1487. http://dx.doi.org/10.1056 /NEJMe058023.
2. Graber CJ, Wong MK, Carleton HA, Perdreau-Remington F, Haller BL, Chambers HF. 2007. Intermediate vancomycin susceptibility in a community-associated MRSA clone. Emerg Infect Dis 13:491-493. http://dx.doi.org/10.3201/eid1303.060960.
3. Jones RN, Sader HS, Flamm RK. 2013. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis 75:304-307. http://dx.doi.org/10.1016/j.diagmicrobio.2012.11.024.
4. Biedenbach DJ, Bell JM, Sader HS, Turnidge JD, Jones RN. 2009. Activities of dalbavancin against a worldwide collection of 81,673 Grampositive bacterial isolates. Antimicrob Agents Chemother 53:1260-1263. http://dx.doi.org/10.1128/AAC.01453-08.
5. Moellering RC, Jr. 2006. The growing menace of community-acquired methicillin-resistant Staphylococcus aureus. Ann Intern Med 144:368-370. http://dx.doi.org/10.7326/0003-4819-144-5-200603070-00014.
6. Moellering RC, Jr. 2008. Current treatment options for communityacquired methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 46:1032-1037. http://dx.doi.org/10.1086/529445.
7. McCurdy SP, Jones RN, Mendes RE, Puttagunta S, Dunne MW. 2015. In vitro activity of dalbavancin against drug-resistant Staphylococcus aureus from a global surveillance program. Antimicrob Agents Chemother 59:5007-5009. http://dx.doi.org/10.1128/AAC.00274-15.
8. Malabarba A, Goldstein BP. 2005. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother 55(Suppl 2):ii15-ii20.
9. Karlowsky JA, Adam HJ, Poutanen SM, Hoban DJ, Zhanel GG, Canadian Antimicrobial Resistance Alliance. 2011. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of theCANWARD2007-2009 study. Diagn Microbiol Infect Dis 69:342-347. http://dx.doi.org/10.1016 /j.diagmicrobio.2010.10.031.
10. Bradley JS, Puttagunta S, Rubino CM, Blumer JL, Dunne M, Sullivan JE. 2015. Pharmacokinetics, safety and tolerability of single dose dalbavancin in children 12-17 years of age. Pediatr Infect Dis J 34:748-752. http://dx.doi.org/10.1097/INF.0000000000000646.
11. Dorr MB, Jabes D, Cavaleri M, Dowell J, Mosconi G, Malabarba A, White RJ, Henkel TJ. 2005. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother 55(Suppl 2):ii25-ii30.
12. Leighton A, Gottlieb AB, Dorr MB, Jabes D, Mosconi G, VanSaders C, Mroszczak EJ, Campbell KC, Kelly E. 2004. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 48:940-945. http://dx.doi.org/10.1128/AAC.48.3.940-945.2004.
13. Raad I, Darouiche R, Vazquez J, Lentnek A, Hachem R, Hanna H, Goldstein B, Henkel T, Seltzer E. 2005. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin Infect Dis 40:374-380. http://dx.doi.org /10.1086/427283.
14. Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T. 2003. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 37:1298-1303. http://dx.doi.org/10.1086/379015.
15. Zervou FN, Zacharioudakis IM, Mylonakis E. 2014. Weekly dalbavancin was noninferior to daily vancomycin for acute bacterial skin infection in adults. Ann Intern Med 161:JC9. http://dx.doi.org/10.7326/0003-4819-161-8-201410210-02009.
16. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. 2014. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 370:2169-2179. http://dx.doi.org/10.1056/NEJMoa1310480.
17. Buckwalter M, Dowell JA. 2005. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol 45:1279-1287. http://dx.doi.org/10.1177/0091270005280378.
18. Jauregui LE, Babazadeh S, Seltzer E, Goldberg L, Krievins D, Frederick M, Krause D, Satilovs I, Endzinas Z, Breaux J, O'Riordan W. 2005. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 41:1407-1415. http://dx.doi.org /10.1086/497271.
19. Salem AH, Zhanel GG, Ibrahim SA, Noreddin AM. 2014. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unitisolated methicillin-resistant Staphylococcus aureus. Clin Exp Pharmacol Physiol 41:437-443. http://dx.doi.org/10.1111/1440-1681.12195.
20. Dowell JA, Goldstein BP, Buckwalter M, Stogniew M, Damle B. 2008. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic. J Clin Pharmacol 48:1063-1068. http://dx.doi.org /10.1177/0091270008321273.
21. Nicolau DP, Sun HK, Seltzer E, Buckwalter M, Dowell JA. 2007. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother 60:681-684. http://dx.doi.org/10.1093/jac/dkm263.
22. Goldstein BP, Jones RN, Fritsche TR, Biedenbach DJ. 2006. Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections. Diagn Microbiol Infect Dis 54:83-87. http://dx.doi.org/10.1016/j.diagmicrobio.2005.09.004.
23. Jones RN, Stilwell MG, Sader HS, Fritsche TR, Goldstein BP. 2006. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn Microbiol Infect Dis 54:149-153. http://dx.doi.org/10.1016/j.diagmicrobio.2005.08.015.
24. Mirza HC, Sancak B, Gur D. 2015. The prevalence of vancomycinintermediate Staphylococcus aureus and heterogeneous VISA among methicillin-resistant strains isolated from pediatric population in a Turkish university hospital. Microb Drug Resist http://dx.doi.org/10.1089/mdr.2015.0048.
25. Saito M, Katayama Y, Hishinuma T, Iwamoto A, Aiba Y, Kuwahara-Arai K, Cui L, Matsuo M, Aritaka N, Hiramatsu K. 2014. "Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3. Antimicrob Agents Chemother 58:5024-5035. http://dx.doi.org/10.1128 /AAC.02470-13.
26. Steinkraus G, White R, Friedrich L. 2007. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 60:788-794. http://dx.doi.org/10.1093/jac/dkm258.
27. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Band JD, White E, Jarvis WR. 1999. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 340:493-501.
28. Sieradzki K, Roberts RB, Haber SW, Tomasz A. 1999. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 340:517-523. http://dx.doi.org/10.1056/NEJM199902183400704.
29. John CC. 1999. Vancomycin resistance in Staphylococcus aureus. N Engl J Med 341:207-208. http://dx.doi.org/10.1056/NEJM199907153410314.
30. Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility testing for bacteria that grow aerobically; approved standard - 10th edition. CLSI document M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
31. Andes D, Craig WA. 2007. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother 51:1633-1642. http://dx.doi.org/10.1128/AAC.01264-06.
32. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-10. http://dx.doi.org/10.1086/516284.